2-CONTROL APS

Their core work

2-CONTROL APS is a Danish technology SME specializing in process control, optimization, and intelligent modeling systems. Their work in COCOP focused on coordinating and optimizing complex industrial processes — the core capability their name signals. In more recent work under Inno4Vac, they have applied AI, in vitro modeling, and manufacturing expertise to accelerate vaccine development, suggesting they offer software or systems that bridge industrial control logic with life-science manufacturing challenges. They operate as a specialized technical contributor in large European R&D consortia rather than as a research organization.

What they specialise in

How they've shifted over time

In their first H2020 project (COCOP, 2016–2020), 2-CONTROL focused on industrial process control and optimization — classic manufacturing territory. By their second project (Inno4Vac, 2021–2027), their keyword profile had shifted entirely toward AI, computational modeling, in vitro systems, and vaccine manufacturing. This is a significant pivot: the same underlying competency in process control and optimization is now being applied in a biotech and health-science context rather than heavy industry.

2-CONTROL appears to be repositioning from general industrial automation toward AI-driven process modeling in the life sciences — a high-value niche where few control-systems SMEs operate.

How they like to work

2-CONTROL has participated in both projects as a consortium partner, never as coordinator, which is consistent with a specialist SME that contributes a specific technical module rather than leading the research agenda. Across just two projects they have accumulated 53 unique partners across 13 countries, suggesting they join large, multi-partner RIA consortia where their control or modeling expertise fills a defined gap. There is no sign of a tight recurring partnership cluster — their network is broad relative to their project count.

Despite only two projects, 2-CONTROL has connected with 53 distinct organizations across 13 European countries, reflecting the large consortium sizes typical of RIA grants. Their geographic reach is genuinely European, with no obvious single-country concentration based on available data.

What sets them apart

2-CONTROL occupies an unusual position as an industrial control-systems SME that has successfully entered the vaccine and biotech manufacturing space — a crossover very few automation companies achieve. Based in Herning, Denmark, outside the main biotech clusters, they bring manufacturing process logic into health-science consortia that are typically dominated by universities and pharma companies. For consortium builders, this makes them a practical bridge between engineering rigor and biotech research pipelines.

Highlights from their portfolio

• COCOP
  Their largest funded project (EUR 298,000) and the clearest expression of their core identity — process control and optimization for complex industrial systems.
• Inno4Vac
  Signals a strategic shift into health-sector manufacturing, combining AI, in vitro modeling, and vaccine development — an unusual move for an industrial control SME.